Pfizer Unveils Internal Restructuring Plans; Reveals Lift of NGF Clinical Hold

Pfizer plans to restructure its commercial operations into three separate business segments — a move one analyst says will better spotlight the value of the company’s various innovative assets. The internal segments include two business lines dedicated to innovative products and a third “value” line for products that have already lost market exclusivity or will before the end of 2015.
Drug Industry Daily